Literatur

I. Leitlinien und Prognose

Dreyling M, Buske C, Cairoli A, et al. Mantelzell-Lymphom. Onkopedia Leitlinie 2026. www.onkopedia.com/de/onkopedia/guidelines/mantelzell-lymphom

Jerkeman M, Aurer I, Campo E, et al; EHA Guidelines Committee and the European MCL Network. EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma. Hemasphere. 2025 Oct 22;9(10):e70233

Tix T, Kumar A, Eyre TA, Dreyling M. Modern Management of Mantle Cell Lymphoma. Am Soc Clin Oncol Educ Book. 2026 Jun;46(3):e517468

Scheubeck G, Jiang L, Hermine O, et al. Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia 2023 Sep;37(9):1887-1894

II. Erstlinientherapie

Martin P, Chadburn A, Christos P et al.: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27:1209-1213, 2009. DOI:10.1200/JCO.2008.19.6121

Hermine O, Jiang L, Walewski J, et al.: High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol 41: 479-484, 2023. DOI:10.1200/JCO.22.01780

Dreyling M, Doorduijn JK, Gine E, et al.: Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network. ASH 2024, Abstract # 240

Kluin-Nelemans HC, Hoster E, Hermine O, et al.: Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-up of the Randomized European MCL Elderly Trial. J Clin Oncol 38:248-256, DOI:10.1200/JCO.19.01294

Wang M, Salek D, Belada Det al. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10;43(20):2276-2284

III. Rezidivtherapie

Visco C, Di Rocco A, Evangelista A, et al.: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia 35:787-795, 2021. DOI:10.1038/s41375-020-01013-3

Wang M, Munoz J, Goy A, et al. Three-Year Follow-up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023 Jan 20;41(3):555-567.

Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. J Clin Oncol. 2025 Jan 20;43(3):318-32.